Scilex Holding Company (SCLX) 10-Year Financial Performance & Capital Metrics

SCLX • • Industrial / General

HealthcareLarge PharmaEarly-Stage & Niche DevelopersClinical-Stage Pain & Specialty Developers

AboutScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.Show more

Revenue $57M +21.1%
EBITDA -$79M +21.7%
Net Income -$73M +36.3%
EPS (Diluted) -19.43 +56.7%
Gross Margin 70.51% +6.1%
EBITDA Margin -140.22% +35.3%
Operating Margin -147.37% +34.7%
Net Margin -128.66% +47.4%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -42.48 +57.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 34.2% free cash flow margin
✓Momentum leader: RS Rating 83 (top 17%)

✗Weaknesses

✗Shares diluted 86.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y21.8%

TTM-26.82%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-328.32%

EPS CAGR

10Y-

5Y-

3Y-

TTM-25.64%

ROCE

10Y Avg-643.7%

5Y Avg-643.7%

3Y Avg-121.47%

Latest-

Peer Comparison

Clinical-Stage Pain & Specialty Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SRXHSRx Health Solutions Inc.	13.22M	0.19	-0.21	28.4%	-9.36%		11.92%
SCLXScilex Holding Company	80.6M	11.46	-0.59	21.07%	-9.31%		24.01%
MIRAMIRA Pharmaceuticals, Inc.	61.14M	1.46	-2.86			-376.4%
CTORCitius Oncology, Inc.	91.58M	1.08	-3.18			-55.19%		0.08

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	23.56M	31.32M	38.03M	46.74M	56.59M
Revenue Growth %	-	0.33%	0.21%	0.23%	0.21%
Cost of Goods Sold+	2.15M	3.63M	10.8M	15.68M	16.69M
COGS % of Revenue	0.09%	0.12%	0.28%	0.34%	0.29%
Gross Profit+	21.41M	27.68M	27.24M	31.06M	39.9M
Gross Margin %	0.91%	0.88%	0.72%	0.66%	0.71%
Gross Profit Growth %	-	0.29%	-0.02%	0.14%	0.28%
Operating Expenses+	56.67M	63.52M	77.87M	136.49M	123.3M
OpEx % of Revenue	2.41%	2.03%	2.05%	2.92%	2.18%
Selling, General & Admin	42.97M	50.58M	64.89M	119.64M	119.02M
SG&A % of Revenue	1.82%	1.62%	1.71%	2.56%	2.1%
Research & Development	9.96M	9.2M	9.05M	12.75M	9.64M
R&D % of Revenue	0.42%	0.29%	0.24%	0.27%	0.17%
Other Operating Expenses	3.74M	3.74M	3.92M	4.11M	-5.36M
Operating Income+	-35.26M	-35.84M	-50.63M	-105.43M	-83.4M
Operating Margin %	-1.5%	-1.14%	-1.33%	-2.26%	-1.47%
Operating Income Growth %	-	-0.02%	-0.41%	-1.08%	0.21%
EBITDA+	-31.48M	-32.06M	-46.18M	-101.28M	-79.35M
EBITDA Margin %	-1.34%	-1.02%	-1.21%	-2.17%	-1.4%
EBITDA Growth %	-	-0.02%	-0.44%	-1.19%	0.22%
D&A (Non-Cash Add-back)	3.78M	3.78M	4.45M	4.15M	4.05M
EBIT	-35.26M	-76.66M	-13.76M	-113.25M	-70.84M
Net Interest Income+	-13.12M	-11.76M	-9.6M	-1.07M	-1.96M
Interest Income	0	0	0	0	0
Interest Expense	13.12M	11.76M	9.6M	1.07M	1.96M
Other Income/Expense	-12.31M	-52.58M	27.27M	-8.89M	10.59M
Pretax Income+	-47.57M	-88.42M	-23.36M	-114.32M	-72.81M
Pretax Margin %	-2.02%	-2.82%	-0.61%	-2.45%	-1.29%
Income Tax+	-53K	5K	4K	13K	-1K
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-47.52M	-88.42M	-23.36M	-114.33M	-72.81M
Net Margin %	-2.02%	-2.82%	-0.61%	-2.45%	-1.29%
Net Income Growth %	-	-0.86%	0.74%	-3.89%	0.36%
Net Income (Continuing)	-47.52M	-88.42M	-23.36M	-114.33M	-72.81M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.01	-23.29	-6.09	-44.85	-19.43
EPS Growth %	-	-1847.41%	0.74%	-6.36%	0.57%
EPS (Basic)	-0.01	-23.29	-6.09	-44.85	-19.43
Diluted Shares Outstanding	4.03M	3.8M	3.83M	3.72M	6.95M
Basic Shares Outstanding	4.03M	3.8M	3.83M	3.72M	6.95M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	22.42M	23M	29.61M	46.78M	41.55M
Cash & Short-Term Investments	4.84M	4.34M	2.18M	3.92M	3.27M
Cash Only	4.84M	4.34M	2.18M	3.92M	3.27M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	13.13M	14.27M	21.24M	34.6M	26.44M
Days Sales Outstanding	203.35	166.29	203.79	270.16	170.55
Inventory	1.15M	2.56M	1.38M	4.21M	2.44M
Days Inventory Outstanding	194.47	257.33	46.58	98.09	53.28
Other Current Assets	0	1.83M	0	0	9.4M
Total Non-Current Assets+	59.08M	54.93M	56.92M	54.53M	51.41M
Property, Plant & Equipment	2.52M	2.11M	1.9M	3.67M	2.93M
Fixed Asset Turnover	9.35x	14.86x	19.99x	12.75x	19.29x
Goodwill	13.48M	13.48M	13.48M	13.48M	13.48M
Intangible Assets	42.54M	38.8M	40.59M	36.48M	32.45M
Long-Term Investments	0	0	0	808K	2.42M
Other Non-Current Assets	538K	538K	944K	89K	119K
Total Assets+	81.5M	77.93M	86.53M	101.31M	92.95M
Asset Turnover	0.29x	0.40x	0.44x	0.46x	0.61x
Asset Growth %	-	-0.04%	0.11%	0.17%	-0.08%
Total Current Liabilities+	78.48M	169.42M	44.84M	250.38M	259.63M
Accounts Payable	8.12M	4.28M	8.45M	40.95M	52.62M
Days Payables Outstanding	1.38K	430.29	285.66	953.27	1.15K
Short-Term Debt	28.9M	58.06M	0	108.43M	34.88M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	26.66M	103.34M	264K	491K	169.04M
Current Ratio	0.29x	0.14x	0.66x	0.19x	0.16x
Quick Ratio	0.27x	0.12x	0.63x	0.17x	0.15x
Cash Conversion Cycle	-981.33	-6.66	-35.28	-585.03	-927.01
Total Non-Current Liabilities+	144.71M	132.39M	5.45M	23.87M	25.96M
Long-Term Debt	107.66M	95.54M	0	17.04M	845K
Capital Lease Obligations	1.65M	1.15M	665K	2.24M	1.52M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	35.4M	30.51M	4.78M	4.59M	20.91M
Total Liabilities	223.19M	301.81M	50.29M	274.25M	285.59M
Total Debt+	138.63M	154.75M	1.41M	128.46M	37.96M
Net Debt	133.79M	150.41M	-774K	124.54M	34.69M
Debt / Equity	-	-	0.04x	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-2.69x	-3.05x	-5.27x	-98.72x	-42.48x
Total Equity+	-141.68M	-223.88M	36.24M	-172.94M	-192.64M
Equity Growth %	-	-0.58%	1.16%	-5.77%	-0.11%
Book Value per Share	-35.15	-58.98	9.45	-46.46	-27.71
Total Shareholders' Equity	-141.68M	-223.88M	36.24M	-172.94M	-192.64M
Common Stock	20K	13K	14K	16K	24K
Retained Earnings	-264.13M	-352.55M	-375.91M	-490.25M	-563.05M
Treasury Stock	0	0	0	-90.52M	-90.52M
Accumulated OCI	0	0	0	0	6.32M
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-31.46M	-28.66M	-21.26M	-20.71M	19.35M
Operating CF Margin %	-1.34%	-0.92%	-0.56%	-0.44%	0.34%
Operating CF Growth %	-	0.09%	0.26%	0.03%	1.93%
Net Income	-47.52M	-88.42M	-23.36M	-114.33M	-72.81M
Depreciation & Amortization	3.78M	3.78M	3.96M	4.15M	4.05M
Stock-Based Compensation	5.39M	5.82M	5.28M	14.6M	15.69M
Deferred Taxes	-800K	12.76M	0	0	0
Other Non-Cash Items	623K	23.79M	-52.8M	9.08M	7.58M
Working Capital Changes	7.06M	13.6M	45.67M	65.8M	64.84M
Change in Receivables	-598K	-1.14M	-6.97M	-13.36M	-6.27M
Change in Inventory	2.38M	-1.42M	1.18M	-2.84M	1.46M
Change in Payables	-4.06M	-3.84M	2.81M	19.88M	7.42M
Cash from Investing+	-25K	0	-2.07M	-330K	-2.67M
Capital Expenditures	-25K	0	-2.07M	-30K	-600K
CapEx % of Revenue	0%	-	0.05%	0%	0.01%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	-300K	0
Cash from Financing+	-19.17M	28.16M	21.17M	23.58M	-18.13M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	18.54M	47.85M	52.33M	-2.6M	1.44M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-31.49M	-28.66M	-23.32M	-21.04M	19.35M
FCF Margin %	-1.34%	-0.92%	-0.61%	-0.45%	0.34%
FCF Growth %	-	0.09%	0.19%	0.1%	1.92%
FCF per Share	-7.81	-7.55	-6.08	-5.65	2.78
FCF Conversion (FCF/Net Income)	0.66x	0.32x	0.91x	0.18x	-0.27x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-64.47%	-	-
Return on Invested Capital (ROIC)	-	-	-107.08%	-	-
Gross Margin	90.88%	88.4%	71.61%	66.45%	70.51%
Net Margin	-201.69%	-282.35%	-61.43%	-244.59%	-128.66%
Debt / Equity	-	-	0.04x	-	-
Interest Coverage	-2.69x	-3.05x	-5.27x	-98.72x	-42.48x
FCF Conversion	0.66x	0.32x	0.91x	0.18x	-0.27x
Revenue Growth	-	32.92%	21.45%	22.9%	21.07%

Frequently Asked Questions

Growth & Financials

Scilex Holding Company (SCLX) reported $40.4M in revenue for fiscal year 2024. This represents a 71% increase from $23.6M in 2020.

Scilex Holding Company (SCLX) grew revenue by 21.1% over the past year. This is strong growth.

Scilex Holding Company (SCLX) reported a net loss of $375.8M for fiscal year 2024.

Dividend & Returns

Scilex Holding Company (SCLX) generated $23.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

← Back to Screener